KURA

Kura Oncology, Inc.

Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.

Kura Oncology, Inc. (KURA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.2
EV / EBITDA -0.7
Rev Growth YoY 10.1%
Gross Margin N/M
Price Return 3M -31.6%
Price Return 12M -30.5%
Catalyst Signal 0.00
Market Cap $682.7M
TTM Revenue $79.3M
Price / Sales 8.6
ROE -224.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B (3.3) C+ (2.7) C (2.4) C+ (2.6) C+ (2.8)
2026-11-06 B- (3.0) B+ (3.6) B- (2.9) C+ (2.8) C+ (2.7) B- (3.0)
2026-10-30 B- (3.0) B+ (3.5) B- (3.0) B (3.4) C+ (2.7) B- (3.1)
2026-10-23 B- (3.0) B+ (3.5) B- (2.9) B- (3.0) C+ (2.6) B- (3.0)
2026-10-16 B- (3.0) B+ (3.5) B- (2.9) B- (2.9) C+ (2.6) B- (3.0)
Page 1 of 4